EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance

Meiting Chen, Riqing Huang, Rishang Chen, Fei Pan, Xiujiao Shen, Haifeng Li, Qixiang Rong, Xin An, Cong Xue, Yanxia Shi iD

The Oncologist · 05.08.2024 · 29 (8) · e957-e966

DOI: 10.1093/oncolo/oyae055 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 04.04.2024. Verfasst von Meiting Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-se…. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunoconjugates, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal sequential strategy for antibody-drug conjugates (ADCs) in breast cancer remains uncertain. This study aimed to evaluate the efficacy and potential resistance of second ADC (ADC2) following the first ADC (ADC1) in human epidermal growth factor receptor 2 (HER2)-positive and HER2-low MBC.

Methods

This retrospective, multicenter, real-world study enrolled patients with MBC who received at least 2 different types of ADCs in 3 hospitals in China between July 1, 2017 and May 1, 2023. Outcomes included the objective response rate (ORR) for ADC1 and ADC2, progression free survival 2 (PFS2), defined as the time from initiation of ADC2 to progression, and overall survival (OS).

Results

Seventy-nine female patients were included, 64 of whom had HER2-positive disease. The ORR for ADC2 with similar payload of ADC1 was found to be 5.3%. When switching to a different payload, the ORR of ADC2 increased to 22.6%. The PFS2 for ADC2 remained similar regardless of whether the payload was similar or different. Switching to different payload showed a higher ORR in patients with rapid progression and a durable response longer than 6 months (41.2% vs 15.0%). Specifically, significantly longer PFS2 and OS were seen in patients treated with trastuzumab deruxtecan (T-Dxd) compared to those treated with disitamab vedotin (RC48) after progression from trastuzumab emtansine (T-DM1; median PFS2 5.37 months vs 3.30 months, HR = 0.40, 95% CI 0.17-0.93, P = .034; median OS 50.6 months vs 20.2 months, HR = 0.27, 95% CI 0.08-0.91, P = .034). For patients who progressed after T-Dxd, the median PFS2 was 6.05 months for those treated with RC48 versus 0.93 months for those treated with T-DM1 (HR = 0.03, 95% CI 0.002-0.353, P = .0093). Genomic analysis revealed that alternation of retinoblastoma1 was significantly associated with superior PFS.

Conclusion

The alternation of payload achieves different responses in different settings. T-Dxd followed by RC48 may be a potentially beneficial strategy in HER2-positive disease. Further research is needed to elucidate the mechanism of cross-resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsImmunoconjugatesDrug Resistance, NeoplasmHumansFemaleMiddle AgedRetrospective StudiesAgedAdultErb-b2 Receptor Tyrosine KinasesTrastuzumabNeoplasm MetastasisProgression-Free SurvivalAged, 80 and over

Stichwörter der Autor:innen

antibody-drug conjugatedisitamab vedotinmetastatic breast cancersacituzumab govitecantrastuzumab deruxtecantrastuzumab emtansine

Substanzen

ImmunoconjugatesErb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
  • Medical Oncology Department III, Central Hospital of Guangdong Nongken, Zhanjiang, People's Republic of China.
  • Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
  • Department of Pathology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.

ORCID-Profile: Yanxia Shi

Zitieren

APA

Chen, M., Huang, R., Chen, R., Pan, F., Shen, X., Li, H., Rong, Q., An, X., Xue, C., & Shi, Y. (2024). Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance. The Oncologist, 29(8), e957-e966. https://doi.org/10.1093/oncolo/oyae055

Vancouver

Chen M, Huang R, Chen R, Pan F, Shen X, Li H, et al. Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance. The Oncologist. 2024;29(8):e957-e966. doi:10.1093/oncolo/oyae055

BibTeX
@article{Chen2024,
  author = {Chen, Meiting and Huang, Riqing and Chen, Rishang and Pan, Fei and Shen, Xiujiao and Li, Haifeng and Rong, Qixiang and An, Xin and Xue, Cong and Shi, Yanxia},
  title = {Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {8},
  pages = {e957--e966},
  doi = {10.1093/oncolo/oyae055}
}
Kostenlos starten →